ZYBAN Prolonged release tablets (2018)
Active ingredients: Bupropion
Product Name and Form
Zyban 150 mg prolonged release tablets.
Prolonged release tablet.
White, film-coated, biconvex, round tablet printed on one side with GX CH7 and plain on the other side.
Qualitative and Quantitative Composition
Each tablet contains bupropion hydrochloride 150 mg.
For the full list of excipients, see section 6.1.
Bupropion is a selective inhibitor of the neuronal re-uptake of catecholamines (noradrenaline and dopamine) with minimal effect on the re-uptake of indolamines (serotonin) and does not inhibit either monoamine oxidase. The mechanism by which bupropion enhances the ability of patients to abstain from smoking is unknown. However, it is presumed that this action is mediated by noradrenergic and/or dopaminergic mechanisms.
Cysteine hydrochloride monohydrate
Titanium dioxide (E171)
Iron oxide black (E172)
Pack sizes and Marketing
Cartons containing cold form foil/foil child-resistant blister packs (PA-Alu-PVC/Paper-Alu).
30, 40, 50, 60 or 100 tablets are supplied in each pack. Each blister strip contains 10 tablets. Not all pack sizes may be marketed.
Glaxo Wellcome UK Ltd. trading as GlaxoSmithKline UK, Stockley Park West, Uxbridge, Middlesex, UB11 1BT, UK
7 June 2000/1 Dec 2004